Home › Funds › B Group, Inc. › PALI
B Group, Inc. position in PALI
PALISADE BIO INC · Health Care
B Group, Inc. reported holding 11,414,285 shares of PALI (PALISADE BIO INC) in its Q2 2026 13F filing — a position valued at US$23.9M, representing 11.20% of its reported portfolio and ranking #3 among its reported holdings. B Group, Inc. has disclosed PALI holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How B Group, Inc.'s PALI position evolved
B Group, Inc. first disclosed a stake in PALI in Q4 2025 at 4,500,000 shares (US$10.6M). The position peaked in Q2 2026 at 11,414,285 shares, worth US$23.9M. Across 3 filings, B Group, Inc. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 11,414,285 shares valued at US$23.9M. Notable position changes include a 154% increase in Q1 2026 (shares rose 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 4.50M | $10.57M | New |
| Q1 2026 | 11.41M | $19.97M | Add |
| Q2 2026 | 11.41M | $23.86M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PALI and 13F data
PALI (PALISADE BIO INC) is a Health Care company. 113 other funds we track also report a position in PALI — the largest reported positions include Soleus Capital Management, L.P. (US$27.3M), Octagon Capital Advisors LP (US$21.5M), Boxer Capital Management, LLC (US$10.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PALI
- Soleus Capital Management, L.P. 13.06M sh · $27.30M · Q2 2026
- Octagon Capital Advisors LP 10.28M sh · $21.48M · Q2 2026
- Boxer Capital Management, LLC 4.80M sh · $10.03M · Q2 2026
- Squadron Capital Management LLC 3.00M sh · $6.27M · Q2 2026
- Propel Bio Management, LLC 2.58M sh · $5.40M · Q2 2026
- GREAT POINT PARTNERS LLC 2.28M sh · $4.78M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 2.26M sh · $4.72M · Q2 2026
- HighVista Strategies LLC 2.03M sh · $4.24M · Q2 2026
- Artia Global Partners LP 1.99M sh · $4.16M · Q2 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 1.73M sh · $3.62M · Q2 2026
- Ally Bridge Group (NY) LLC 1.23M sh · $2.57M · Q2 2026
- Creek Drive Management Group LLC 440.00K sh · $919.60K · Q2 2026
More on B Group, Inc.
FAQ
How long has B Group, Inc. held PALI?
B Group, Inc. has disclosed PALI holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is B Group, Inc.'s current position in PALI?
As of Q2 2026, B Group, Inc. holds 11.41M shares of PALI (PALISADE BIO INC), valued at $23.86M, representing 11.20% of its reported portfolio and ranking #3.
Has B Group, Inc. been buying or selling PALI?
In the latest 13F filing (Q2 2026), B Group, Inc. held unchanged its position in PALI. The position peaked in Q2 2026 at 11.41M shares.
Which other funds hold PALI?
Other major institutional holders of PALI include Soleus Capital Management, L.P., Octagon Capital Advisors LP, Boxer Capital Management, LLC, among 113 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.